Scott Watkins
Psychiatric/Mental Health · Nampa, IDNPI 1760950604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,621 of the $10,822 with a category attached, or 88.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $32.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$2K
- Corium, LLC$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$572
- plus $3K from 14 others
What the payments were for
- Consulting fees$1732%
- Speaking & faculty fees$8057%
- Travel & lodging$380%
- Food & beverage$9,62189%
- Education$1862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $1,869 |
| AbbVie | 73 | $1,637 |
| Corium, LLC | 26 | $1,489 |
| Alkermes, Inc. | 32 | $1,235 |
| Otsuka America Pharmaceutical, Inc. | 33 | $1,164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $572 |
| E.r. Squibb & Sons, L.L.C. | 14 | $539 |
| Teva Pharmaceuticals USA, Inc. | 20 | $531 |
| Vanda Pharmaceuticals Inc. | 18 | $410 |
| Supernus Pharmaceuticals, Inc. | 16 | $322 |
| Neurocrine Biosciences, Inc. | 4 | $311 |
| Axsome Therapeutics, Inc. | 4 | $168 |
| Ironshore Pharmaceuticals Inc. | 7 | $129 |
| Neuronetics, Inc. | 1 | $126 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| Tris Pharma Inc | 4 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $66 |
| Indivior Inc. | 3 | $51 |
| Pfizer | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,752
- INVEGA SUSTENNA$1,170
- Azstarys$1,095
- VRAYLAR$684
- ARISTADA$413
- ABILIFY MAINTENA$347
- ABILIFY ASIMTUFII$347
- REXULTI$345
- INGREZZA$259
- CAPLYTA$232
- COBENFY$131
- SPRAVATO$127
- NEUROSTAR TMS THERAPY$126
- INVEGA TRINZA$118
- Auvelity$118
- UZEDY$113
- VIVITROL$106
- ARISTADA INITIO$103
- QELBREE$101
- Fanapt$101
How this compares
$10,822 in reported general payments places this provider in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 26 | $85,897 |
| Abilify AsimtufiiAripiprazole | 12 | $67,591 |
| CaplytaLumateperone Tosylate | 26 | $50,214 |
| BelsomraSuvorexant | 53 | $24,192 |
| VraylarCariprazine Hcl | 13 | $17,558 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,034 |
| TrintellixVortioxetine Hydrobromide | 18 | $11,323 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $6,602 |
| Lurasidone Hcl | 32 | $6,243 |
| Aripiprazole | 67 | $5,916 |
| Lisdexamfetamine Dimesylate | 21 | $3,612 |
| Vilazodone Hcl | 28 | $3,518 |
| Fluphenazine Decanoate | 20 | $3,159 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $3,156 |
| Escitalopram Oxalate | 21 | $3,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,869 | $85,89726 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $1,164 | $67,59112 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $572 | $50,21426 claims |
| AbbVieVraylar | $1,637 | $17,55813 claims |
| Alkermes, Inc.Lybalvi | $1,235 | $17,03411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Nampa
- Becky BoleNampa$6K
- Matthew FowlerNampa$3K
- Jason MartinIdaho Falls$78K
- Misti NewsonBoise$56K
- Jared PetrickCoeur D Alene$32K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Ashley CroftCaldwell$13K
- Julie SchraderBoise$9K
- Susan DayBoise$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.